Synsorb won' test E. coli-related drug

Article Abstract:

Drug development company Synsorb Biotech Inc of Calgary, Alberta, has annnouced that it will not go ahead with the planned testing of its Sysnsorb Px drug as treatment for diarrhea caused by the E coli bacteria. The company said that the US Food and Drug Administration has indicated that a single test would not be enough to support filing a drug application. Synsorb is also currently testing the drug in a Phase III trials against a toxic strain of E coli to prevent hemolytic uremic syndrome.

Antidiarrheals, Synsorb Biotech Inc.

---

Bioniche shares soar on E. coli vaccine news

Article Abstract:

The article discusses how Bioniche Life Sciences Inc.'s shares increased 22% yesterday, after shareholders were told about the company's development of a new cattle vaccine to protect humans from E. coli infections.

Securities issued, listed, Vaccines for Human Use, Securities, Vaccines, Bioniche Life Sciences Inc.

---

Biomira shares jump 16%

Article Abstract:

Biomira Inc. saw its share value rise by 16% after the company secured an investment from Merck KGaA for the development of cancer vaccines. Merck invested US$150 million for the development of two Biomira vaccines.

Germany, Receipt of funds, Pharmaceutical preparations, Vaccines & Antigens for Human Use, Biological Product (except Diagnostic) Manufacturing, Anticancer Drugs, Use of Funds, Pharmaceutical industry, Investments, Biological products, Antineoplastic agents, Merck KGAA, Biomira Inc.

Similar abstracts:

• Abstracts: Investors buy biotechs on news of merger. Biotech, oil, bank shares boost TSE
• Abstracts: Corel in pact with Microsoft. Corel shares jump on bundling deal. FastLane set to sign deal with Microsoft
• Abstracts: Chancery opens portal to education information. Software firms' share slide. ACD focuses on revenue stream
• Abstracts: Torstar in no hurry to join `expensive' convergence race. Torstar shares slide 4%. Bad news for Canada's publishing titans
• Abstracts: Small Chapters investors have cause for optimism. Trilogy extends hostile bid for Chapters

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.